Boehringer Respimat May Challenge Glaxo, Novartis in Respiratory Disease

By Sam Fazeli, Bloomberg Industries

 

Boehringer Ingelheim may join Novartis in challenging GlaxoSmithKline’s dominance in the treatment of respiratory diseases with new safety data on its Respimat device. While the data may not stave off generic competition for one of its top-selling drugs, Spiriva, it may allow Boehringer to develop a competitive combination therapy.

Read more >> 

Bloomberg BRIEF Newsletters